Drugs / PA3-17
Trials 3
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 12 trials | ||||||
| Phase 1 | NCT07623681 | Jun 2026 overdue | T lymphoblastic leukemia/lymphoma | PersonGen BioTherapeutics (Suzhou) Co., Ltd. | Not yet recruiting | No outcome recorded |
| Phase 1 | NCT05170568 | Dec 2021 → Dec 2022 | refractory hematologic cancer | PersonGen BioTherapeutics (Suzhou) Co., Ltd. | Unknown | No outcome recorded |
| Phase 21 trial | ||||||
| Phase 2 | NCT07188610 | Sep 2025 → Oct 2026 expected | T lymphoblastic leukemia/lymphoma | PersonGen BioTherapeutics (Suzhou) Co., Ltd. | Recruiting | No outcome recorded |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 3 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | PA3-17 | “The primary objectives are to assess the safety of PA3-17 injection in pediatric and adolescent participants with relapsed/refractory T-lymphoblastic leukemia/lymphoma, and...” NCT07623681 ↗2“safety and tolerability of PA3-17 injection in adult subjects with CD7-positive relapsed/refractory lymphoid hematologic malignancies” NCT05170568 ↗ “a single infusion of PA3-17 injection will be administered” NCT07188610 ↗ |
| Known as | PA3-17 injection | “The primary objectives are to assess the safety of PA3-17 injection in pediatric and adolescent participants with relapsed/refractory T-lymphoblastic leukemia/lymphoma, and...” NCT07623681 ↗ |
| Modality | Cell therapy | “1×10\^6 CAR-T cells/kg” NCT07623681 ↗ |
| Target | CD7 | “T cell injection targeting CD7 chimeric antigen receptor” NCT07623681 ↗ |